Capacity of neutrophils and monocytes from human immunodeficiency virus-infected patients and healthy controls to inhibit growth of Mycobacterium bovis.
We compared the differences in growth inhibition of Mycobacterium bovis by monocytes and neutrophils from human immunodeficiency virus (HIV)-infected persons (n = 12; mean CD4 count = 451/mm(3)) and healthy controls (n = 6). Phagocytes from all HIV-infected patients were incubated with or without exogenous granulocyte-macrophate colony-stimulating factor (GMCSF; 500-1000 U/mL). In two of the HIV-infected patients, phagocytes were incubated with or without interleukin (IL)-2 or IL-8 (500-1000 U/mL). Compared with that in HIV-infected patients, the reduction of M. bovis growth at 24 hours was 81% greater among monocytes and 69% greater among neutrophils from healthy controls (P =.03 and.04, respectively). Among HIV-infected patients, we noted greater mycobacterial reduction in monocytes (49%, P =.04) and neutrophils (42%, P =.05) from the early-stage patients (mean CD4 count = 760/mm(3)) compared with that in late-stage patients (mean CD4 count = 172/ mm(3)). Incubation with GM-CSF, IL-2, or IL-8 did not augment mycobactericidal activity. These findings suggest that the capacity of neutrophils and monocytes from HIV-infected patients to inhibit the growth of M. bovis is impaired, and this impairment is more pronounced in later stages of HIV infection.
Kaul
Daniel
D
Divisions of Infectious Diseases Pulmonary Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arobor 48109, USA.
Coffey
Michael J
MJ
Phare
Susan M
SM
Kazanjian
Powel H
PH
D016022:Case-Control Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology; D016209:Interleukin-8 / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D009163:Mycobacterium bovis / Q000254:growth & development*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D010586:Phagocytes / Q000187:drug effects / Q000276:immunology
D007376:Interleukin-2; D016209:Interleukin-8; D016178:Granulocyte-Macrophage Colony-Stimulating Factor